Even when NLRP3 inhibition or IL-1R blockade could not eliminate the malignant clone, this therapy could reduce the symptoms of patients such as massive splenomegaly, unexplained fever and failure to thrive, which would be a major benefit for the patients and bring them into a condition that is more stable before undergoing the potentially curative allo-HCT. The gene discussed is IL1R1; the disease is Splenomegaly.